What Does a Tirzepatide Weight Loss Trial Show?
A tirzepatide weight loss trial found that participants without diabetes lost an average of 15.0% to 20.9% of their body weight over 72 weeks, depending on the treatment group, while the placebo group lost 3.1%. These are group averages from a study that included dose escalation and lifestyle support, not a forecast for any individual or a measure of first-month weight loss.
How much weight did people lose in the tirzepatide weight loss trial?
In SURMOUNT-1, average weight change at week 72 ranged from 15.0% to 20.9% across the tirzepatide groups, compared with 3.1% in the placebo group. The New England Journal of Medicine reported those results in 2022. The study randomized 2,539 adults with obesity or overweight and a weight-related complication, without diabetes, to weekly treatment or placebo.
The differences by group matter: the reported averages were 15.0% for the 5-mg group, 19.5% for the 10-mg group, and 20.9% for the 15-mg group. In the placebo group, average weight change was −3.1%. These are averages for groups in a controlled study, not a promise that an individual will lose a particular percentage.
A second way to read the results is to look at how many participants reached a threshold. At least 20% weight loss was achieved by 30.0%, 50.1%, and 56.7% in the respective 5-, 10-, and 15-mg groups, compared with 3.1% in the placebo group (SURMOUNT-1, 2022). A group average and the share reaching a threshold answer different questions; neither tells you what will happen to one person.
| SURMOUNT-1 group | Average weight change at week 72 | Participants reaching at least 20% loss |
|---|---|---|
| 5 mg tirzepatide | −15.0% | 30.0% |
| 10 mg tirzepatide | −19.5% | 50.1% |
| 15 mg tirzepatide | −20.9% | 56.7% |
| Placebo | −3.1% | 3.1% |
How long did the tirzepatide weight loss trial last?
SURMOUNT-1 lasted 72 weeks, or about a year and four months, according to the 2022 New England Journal of Medicine report. The trial included a 20-week dose-escalation period, so the week-72 result reflects a long study period that included gradually increasing treatment, rather than a short-term snapshot.
Participants also received lifestyle support: counseling, a planned daily calorie deficit of 500 calories, and a target of at least 150 minutes of physical activity each week (SURMOUNT-1, 2022). That context is important when comparing trial results with everyday expectations. The reported outcome represents the study’s treatment and support conditions together.
The length of follow-up also changes what a result can tell you. A week-72 average describes weight change over the trial period; it does not reveal a guaranteed month-by-month pattern. For readers weighing whether to participate in a study, What Should I Know Before Consenting to an Obesity Medication Trial? is a relevant companion to reviewing eligibility, study procedures, and participation details.
How long might it take to lose 20 pounds on tirzepatide, based on trial results?
The trial results do not establish a reliable timeline for an individual to lose 20 pounds. SURMOUNT-1 reported average percentage changes at week 72, but it did not provide an individual timetable or a first-month rate that can be used to calculate when a particular person would reach that amount.
For scale, the study reported that 30.0% to 56.7% of participants in the tirzepatide groups reached at least 20% weight loss by week 72, depending on group (SURMOUNT-1, 2022). That is a percentage-of-body-weight threshold, not a fixed 20-pound target. The same pound change represents a different percentage for people at different starting weights, and a group result cannot be converted into a personal schedule.
So the practical answer is not “a certain number of weeks.” The evidence supports describing outcomes over the full 72-week trial, with treatment escalation and lifestyle support; it does not support predicting how quickly one person will lose a set number of pounds.
How much weight did participants lose in the first month of the trial?
The provided SURMOUNT-1 results do not report a first-month average, so they cannot establish how much participants lost during that month. The published key results report average changes at week 72, and the trial included a 20-week dose-escalation period (New England Journal of Medicine, 2022).
This is a useful distinction when reading headline trial numbers. A long-term average is not a monthly rate: dividing the final percentage by the number of months would imply steady progress that the cited results do not show. The first-month question therefore has no supported numerical answer from these trial findings.
Trial design also shapes the answer. SURMOUNT-1 paired treatment with counseling, a planned 500-calorie daily deficit, and at least 150 minutes of weekly activity, according to the 2022 report. Its final averages describe the whole study context, not an isolated month or a stand-alone expectation for routine care.
Frequently Asked Questions
What happened to participants who stopped tirzepatide in SURMOUNT-4?
In SURMOUNT-4, 783 adults began a 36-week open-label lead-in, and 670 who qualified were randomized to continue treatment or switch to placebo for another 52 weeks. From week 36 to week 88, those switched to placebo regained an average of 14.0%, while those continuing lost a further 5.5% (JAMA, 2023). The result applies to people who completed the lead-in and tolerated treatment, not necessarily every person who stops.
By week 88, 16.6% of those switched to placebo had maintained at least 80% of their lead-in weight loss, compared with 89.5% of those who continued (JAMA, 2023). Because this was a randomized-withdrawal design after a lead-in, it directly compared continuation with switching among those who qualified; it does not establish an individual outcome after stopping.
How do trial results differ for people with type 2 diabetes?
SURMOUNT-2 studied adults with type 2 diabetes for 72 weeks and reported average weight changes of −12.8% in the 10-mg group and −14.7% in the 15-mg group, compared with −3.2% for placebo (The Lancet, 2023). At least 5% weight loss occurred in 79–83% of the tirzepatide participants, versus 32% of placebo participants.
These figures should not be treated as a direct head-to-head comparison with SURMOUNT-1. The Lancet report involved participants with type 2 diabetes and tested the 10- and 15-mg groups, while SURMOUNT-1 enrolled people without diabetes and included a 5-mg group. Different populations and study designs make simple comparisons misleading.
Can I find or join a tirzepatide weight loss trial near me?
ClinicalTrials.gov provides tools to search studies by condition or other terms and narrow results by location and study status. Its listings can include a study’s purpose, eligibility information, locations, and contact details (ClinicalTrials.gov, accessed for this guide). NIH also directs people seeking studies beyond NIH facilities to the registry and advises using its information alongside advice from health care professionals (NIH, accessed for this guide).
Search results are a starting point, not an eligibility decision. Check the listing and contact the study team to confirm current locations, requirements, and participation details, then discuss potential risks and benefits with a clinician. The National Institutes of Health notes that registry information should be used in conjunction with health care professional advice.
Sources
- The New England Journal of Medicine — SURMOUNT-1
- JAMA — SURMOUNT-4 randomized clinical trial
- The Lancet — SURMOUNT-2
- ClinicalTrials.gov — How to Search for Clinical Studies
- National Institutes of Health — Finding a Clinical Trial
Disclaimer: This article is for general information only and is not medical advice. It is not a substitute for diagnosis or treatment by a qualified healthcare professional. Always speak to your doctor before acting on anything you read here.
Read next
Should I Join a Weight-Loss Clinical Trial?
A practical guide to finding, evaluating, and asking the right questions about weight-loss clinical trials.
Should I Join a Weight-Loss Clinical Trial?
A practical guide to finding, evaluating, and consenting to a weight-loss clinical trial, including placebo, eligibility, costs, and safety questions.
Which Prescription Weight-Loss Medication Is Most Effective?
Evidence-based comparison of Wegovy and Zepbound, including effectiveness, side effects, eligibility, lean mass, and treatment planning.
How Can I Tell if Persistent Respiratory Symptoms Warrant a Lung-Cancer Evaluation?
How to recognize persistent respiratory symptoms that merit lung-cancer evaluation and distinguish screening from diagnostic testing.